Bristol Myers Squibb reports positive phase 3 trial results

robot
摘要生成中

Bristol Myers Squibb announced positive interim Phase 3 results for its SUCCESSOR-2 study, which evaluated oral mezigdomide combined with carfilzomib and dexamethasone for relapsed or refractory multiple myeloma. The study demonstrated significant improvement in progression-free survival and is the first positive Phase 3 study for mezigdomide and the second for the company’s CELMoD program. Bristol Myers Squibb’s stock has surged over 30% in the past six months, and the company has a “GREAT” financial health score according to InvestingPro.

此頁面可能包含第三方內容,僅供參考(非陳述或保證),不應被視為 Gate 認可其觀點表述,也不得被視為財務或專業建議。詳見聲明
  • 讚賞
  • 留言
  • 轉發
  • 分享
留言
請輸入留言內容
請輸入留言內容
暫無留言